Survival outcomes in the PRIME study for patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC), by baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS).

Abstract

3557^ Background: In PRIME, panitumumab (pmab) + FOLFOX4 improved overall survival (OS) for RAS WT mCRC pts vs FOLFOX4 alone (Douillard et al 2013). Prespecified subgroup analysis identified only E...